04040nam 22006855 450 991087898300332120240802130230.09789819734467(electronic bk.)978981973445010.1007/978-981-97-3446-7(MiAaPQ)EBC31579350(Au-PeEL)EBL31579350(CKB)33601168500041(DE-He213)978-981-97-3446-7(EXLCZ)993360116850004120240802d2024 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierAnalysis File of Drug-Induced Lung Injury Expert Opinion for Analysis of Big Data /by Akihiko Gemma1st ed. 2024.Singapore :Springer Nature Singapore :Imprint: Springer,2024.1 online resource (122 pages)Print version: Gemma, Akihiko Analysis File of Drug-Induced Lung Injury Singapore : Springer,c2024 9789819734450 Part I Understanding Drug-Induced Lung Injuries -- 1 Understanding Drug-Induced Lung Injuries -- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug -- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib) -- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab) -- 4 mTOR inhibitors (temsirolimus, everolimus) -- 5 Proteasome inhibitor (bortezomib) -- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab) -- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab) -- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.) -- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan) -- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.Respiratory organsDiseasesMedical geneticsDiseasesCauses and theories of causationOncologyPharmacologyGeneticsResearchPneumologyClinical GeneticsPathogenesisOncologyPharmacologyGenetics ResearchRespiratory organsDiseases.Medical genetics.DiseasesCauses and theories of causation.Oncology.Pharmacology.GeneticsResearch.Pneumology.Clinical Genetics.Pathogenesis.Oncology.Pharmacology.Genetics Research.616.2Gemma Akihiko1765048MiAaPQMiAaPQMiAaPQ9910878983003321Analysis File of Drug-Induced Lung Injury4206281UNINA